NEW YORK, Nov 5 (Reuters) - Shares of BioCryst Pharmaceuticals Inc (BCRX.O) rose 5.4 percent to $10.65 in premarket trading on Thursday, after the company received its first Peramivir order from the U.S. government.
(Reporting by Ryan Vlastelica)
© Thomson Reuters 2009 All rights reserved.
UK
USuk.reuters.com
Help and Contact Us |
Advertise With Us |
Mobile |
Newsletters |
RSS
|
Interactive TV |
Labs |
Archive |
Site Index |
Video Index
Thomson Reuters Corporate: Copyright | Disclaimer | Privacy | Professional Products | Professional Products Support | About Thomson Reuters | Careers
International Editions: Africa | Arabic | Argentina | Brazil | Canada | China | France | Germany | India | Italy | Japan | Latin America | Mexico | Russia | Spain | United Kingdom | United States
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
London jewellers weigh Dubai crisis